← All writing

ARTICLE 92·DEVELOPMENT, TECHNOLOGY AND PEOPLE

India’s Medical Diplomacy and Affordable Medicines

India’s pharmaceutical sector gives the country a meaningful role in global health. Its companies produce generic medicines, vaccines, active pharmaceutical ingredients and medical devices for markets around the world. This manufacturing base can support access to…

Original editorial illustration for article 92: India’s Medical Diplomacy and Affordable Medicines.
Original editorial illustration by Ibrahim Javaid. Conceptual scene, not to scale.

INTERACTIVE 3D EXPLAINERDevelopment, technology and people

A closer look at the argument.

Open each layer to move from the article’s question, through its evidence, to the conclusion and limits.

01The question

India’s pharmaceutical sector gives the country a meaningful role in global health. Its companies produce generic medicines, vaccines, active pharmaceutical ingredients and medical devices for markets around the world. This manufacturing base can support access to treatment and strengthen diplomatic partnerships. The case for India as a health partner depends, however, on…

Read the article and sources
02The record

India exported US$30.47 billion in pharmaceutical products in FY 2024–25, according to the Department of Commerce. Government sources report that Indian medicines reached 191 countries that year. These figures show the scale of trade, but export value does not directly measure how many people gained access to medicines or whether health systems could afford them. (PIB…

Read the article and sources
03What follows

India’s medical diplomacy is strongest when commercial exports are paired with public-health cooperation. The country can support affordable access, but it should avoid equating low cost with equitable care. Quality regulation, local production where feasible, transparent procurement and predictable supply all matter. India’s manufacturing scale is a strategic asset; its…

Read the article and sources

India’s pharmaceutical sector gives the country a meaningful role in global health. Its companies produce generic medicines, vaccines, active pharmaceutical ingredients and medical devices for markets around the world. This manufacturing base can support access to treatment and strengthen diplomatic partnerships. The case for India as a health partner depends, however, on quality, regulatory trust and reliable supply—not on low prices alone.

India exported US$30.47 billion in pharmaceutical products in FY 2024–25, according to the Department of Commerce. Government sources report that Indian medicines reached 191 countries that year. These figures show the scale of trade, but export value does not directly measure how many people gained access to medicines or whether health systems could afford them. (PIB: pharmaceutical exports in FY 2024–25; Economic Survey pharmaceutical export factsheet)

Generic competition can lower treatment costs when medicines meet quality standards and multiple suppliers are available. India’s firms supply products used in HIV treatment, tuberculosis care, cancer therapy and routine primary healthcare. International procurement agencies and regulators rely on quality assurance, manufacturing inspections and stable supply agreements. A medicine that is inexpensive but unavailable, substandard or difficult to monitor cannot deliver health security.

Medical diplomacy includes more than exports. India has supplied medicines, diagnostic kits and protective equipment during emergencies, shared technical expertise and supported healthcare projects in partner countries. Vaccine Maitri during the COVID-19 pandemic is one prominent example of manufacturing capacity translated into international assistance. Partnerships in training, telemedicine and pharmaceutical regulation can support longer-term capacity, particularly when they respond to needs identified by local health authorities.

The sector also faces vulnerabilities. India depends on imports for some active ingredients and intermediates, and concentrated sourcing can threaten production during geopolitical or logistical disruptions. The government has introduced incentives to expand domestic manufacturing, but resilience requires competitive production, environmental safeguards and strong quality oversight. Export controls during a domestic shortage may be necessary, yet sudden restrictions can disrupt hospitals and buyers abroad. Clear criteria and communication help preserve trust.

Quality assurance is the foundation of access. A generic medicine can improve affordability only if it is safe, effective and consistently manufactured. Regulators need inspection capacity, transparent standards, dependable laboratory testing and systems for tracking adverse events. India’s reputation as a major supplier depends on confidence in manufacturing at home and in importing countries. Companies and public agencies should treat quality investment as a core export capability, while regulators must be able to act when products fail to meet standards.

Access also depends on how medicines reach patients. Procurement systems, insurance coverage, distribution networks and trained health workers shape whether a low-cost drug is actually available at the clinic. India can cooperate with partner governments on regulatory training, pooled procurement and local distribution, but programs should fit national health plans and budgets. Donations can address urgent gaps; long-term access is more sustainable when there are dependable purchasing arrangements and local capacity to forecast and manage supplies.

A resilient pharmaceutical sector requires attention to upstream inputs. India imports some active pharmaceutical ingredients and intermediates, leaving manufacturers exposed to concentrated supply or shipping disruptions. Domestic production incentives may reduce that risk, but firms need competitive quality, reliable utilities and environmental controls. Diversified imports, strategic stocks of selected inputs and recycling or process innovation can add options. Policy evaluation should compare the cost of resilience with the public-health impact of shortages, rather than treating self-sufficiency as an end in itself.

International health cooperation should build trust through accurate claims. Export totals and the number of destination countries show reach, while patient affordability, quality and continuity require different evidence. India can publish procurement data, quality certifications and supply reliability indicators where available. Where medicines are provided through aid, partners should be consulted about the products, quantities and distribution plan. Such transparency allows the government to present its contribution strongly without equating commercial activity with improved health outcomes in every recipient country.

The strongest long-term contribution may combine Indian manufacturing with local skills and regulatory capacity. Technical exchanges, joint research, training for pharmacists and support for quality laboratories can help partner countries oversee medicines themselves. Technology transfer should be commercially realistic and respect intellectual property and local laws. These partnerships create stronger health systems and stable demand while preserving India’s role as a supplier. Their success should be assessed by reliable treatment access and the ability of institutions to sustain the work after initial support ends.

The government can strengthen confidence by publishing a concise account of medicine shortages and export controls when they are used. Emergency restrictions may protect domestic patients, but affected foreign buyers need notice and clarity about duration and exemptions. Transparent consultation with manufacturers, hospitals and partner governments can reduce disruption. This demonstrates that India’s commitment to affordable medicines includes predictable conduct as well as manufacturing scale.

India’s medical diplomacy is strongest when commercial exports are paired with public-health cooperation. The country can support affordable access, but it should avoid equating low cost with equitable care. Quality regulation, local production where feasible, transparent procurement and predictable supply all matter. India’s manufacturing scale is a strategic asset; its reputation will depend on whether that scale consistently serves patients safely and reliably.

Sources